Vytrus Biotech Achieves Record Growth and Global Recognition in Q1 2025

Vytrus Biotech, a company specializing in plant- based biotechnology – derived active ingredients for the cosmetics industry, has presented its unaudited earnings report for the first quarter of 2025 , recording solid sales growth of 76 % year – over – year.

This momentum has been widespread across all geographic areas where the biotech company operates. The European Union, including Spain, experienced a 64 % increase, while in the United States, growth reached 27 %. Particularly notable was the performance of Vytrus Biotech in the Asia – Pacific region, which increased sales by 271 % , with India as the main driver. In Latin America, key markets such as Brazil, Colombia, and Mexico contributed to a 56 % growth for Vytrus Biotech.

Thanks to these results, Vytrus Biotech has surpassed € 5.9 million in year – on – year sales for the first time. This progress has been accompanied by a significant improvement in profitability, with EBITDA doubling ( + 102 %) compared to the first quarter of 2024, reaching € 1.02 million.

Products with Exosomic Peptides technology have been key drivers of growth in the quarter, especially in the anti- aging, hair care , and brightening categories. In total, the company now sells its solutions in 42 countries.

On a strategic level, Vytrus Biotech maintains its ambitious goal of tripling its sales to € 12 million and quadrupling its EBITDA to € 5 million by 2027, as established in its Strategic Plan launched in 2024.​

Vytrus Biotech: International recognition for innovation​

The month of April also marked a milestone for Vytrus in the field of innovation. The company launched Clarivine , a new 100% natural active ingredient based on grape stem cells , developed using advanced plant biotechnology. The product simulates the effects of intermittent fasting on skin cells, promoting regeneration, even skin tone, hydration, and wrinkle reduction in just 14 days.

Clarivine was awarded the Silver Best Ingredient Award at the Innovation Awards of in- cosmetics Global 2025, held in Amsterdam, being chosen from more than 200 international innovations.

This recognition is complemented by the awards received by two of the brand ‘s other star ingredients, Centella Reversa and Capilla Longa , at the prestigious BSB Innovation Awards 2025, also held in the Dutch capital. Both formulas stand out for their natural plant exosome content and consolidate Vytrus as a leader in sustainable and innovative cosmetics.

With the launch of Clarivine, Vytrus Biotech reaches 22 active ingredients on the market, consolidating its position as a key player in the cosmetic biotechnology sector.

__

(Featured image by Louis Reed via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in IPMARK. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us